Related Experiment Video
Updated: Aug 12, 2026
08:49
Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
Published on: January 22, 2019
The first naturally occurring Tie2 kinase inhibitor
B N Zhou1, R K Johnson, M R Mattern
1Department of Chemistry, M/C 0212, Virginia Polytechnic Institute and State University, Blacksburg, Virginia 24061, USA.
Organic Letters
|December 12, 2001
Summary
Researchers discovered a new compound from Acacia aulacocarpa that inhibits Tie2 tyrosine kinase. This novel triterpene is the first natural, non-protein inhibitor of this important enzyme.
Area of Science:
- Natural Product Chemistry
- Biochemistry
- Pharmacology
Background:
- Tie2 tyrosine kinase plays a crucial role in vascular development and is a target for therapeutic intervention.
- Identifying novel inhibitors of Tie2 kinase is essential for developing new treatments for angiogenesis-related diseases.
- Natural products represent a rich source of diverse chemical structures with potential biological activities.
Purpose of the Study:
- To isolate and characterize novel compounds from Acacia aulacocarpa with Tie2 tyrosine kinase inhibitory activity.
- To identify the first naturally occurring non-protein inhibitor of Tie2 kinase.
- To evaluate the anti-proliferative effects of the isolated compound on cultured mammalian cells.
Main Methods:
- Bioassay-guided fractionation of Acacia aulacocarpa extract.
- Assay for Tie2 tyrosine kinase inhibitory activity.
- Structure elucidation using spectral data analysis (e.g., NMR, Mass Spectrometry).
Main Results:
- Isolation of a novel triterpene, 3,21-dioxo-olean-18-en-oic acid (1).
- Compound 1 was identified as the first naturally occurring non-protein inhibitor of Tie2 kinase.
- Compound 1 demonstrated modest activity against various cultured mammalian cells.
Conclusions:
- Acacia aulacocarpa yields a novel triterpene inhibitor of Tie2 tyrosine kinase.
- 3,21-dioxo-olean-18-en-oic acid represents a significant discovery in the field of kinase inhibitors.
- The compound's dual activity warrants further investigation for potential therapeutic applications.
More Related Videos
Related Concept Videos
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
02:15M-Cdk Drives Transition Into Mitosis
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:26Receptor Tyrosine Kinases
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
01:22PI3K/mTOR/AKT Signaling Pathway
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include: